Pfizer Reports Strong Cash Flow and Sales Growth Amid Dividend Increase in August 2025

Pfizer, a small-cap player in the Pharmaceuticals & Biotechnology industry, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 13, 2025, indicate a notable shift in the company's evaluation, with its score adjusting from 8 to 6 over the past three months.
The financial data reveals several positive aspects for Pfizer. The company achieved its highest operating cash flow in three years, amounting to Rs 659.75 crore, reflecting robust cash generation from its core business operations. Additionally, net sales reached Rs 603.05 crore, marking the highest quarterly figure in the last five quarters, suggesting a favorable near-term sales trend. Profit After Tax (PAT) also showed growth, recorded at Rs 191.75 crore, which represents a 21.1% increase compared to the average PAT of the previous four quarters. Furthermore, Pfizer has increased its annual dividend per share to Rs 165.00, the highest in five years, alongside a dividend payout ratio of 119.20%, indicating a significant distribution of profits to shareholders.

However, the company also reported a rise in non-operating income, which reached Rs 67.17 crore in the last five quarters. This increase may not be sustainable, raising questions about the long-term viability of such income sources.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.